Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports

Table 2 Patients who completed sofosbuvir/velpatasvir/voxilaprevir after liver transplant

Patient No.	GT	Pre-transplant child-pugh	Previous therapies	LOT (wk)	Time to start (d)	SVR 12	ACR
1	1a/4	B	L/S	24	31	Yes	No
2	1/4	B	IFN/RBV		106	Yes	No
			SOF/RBV
			L/S	24
3	1b	B	L/S	12	132	Yes	No
4	1b	A	L/S	12	256	Yes	No
5	1/4	B	S/S	12	120	Yes	No
			L/S	24
6	1a	1	L/S	12	7853	Yes	No
			E/G2	16

¹Liver transplant was performed at another hospital and pathology records were not available.

²Indicates treatment was after transplant.

³Prolonged time as patient had been lost to follow-up between her transplant at a different institute and establishing care at our institute.

L/S: Ledipasvir/sofosbuvir; S/S: Simeprevir/sofosbuvir; E/G: Elbasvir/grazoprevir; SOF: Sofosbuvir; IFN: Interferon; RBV: Ribavirin; GT: Genotype; LOT: Length of treatment; Treatment start: Number of days after transplant that sofosbuvir/velpatasvir/voxilaprevir therapy was initiated; ACR: Acute cellular rejection after starting sofosbuvir/velpatasvir/voxilaprevir; SVR 12: Undetectable virus 12 wk after completion of therapy.